Correlation between glycemic control markers and lipid profile in type 2 diabetes mellitus and impaired glucose tolerance

Satish Basanagouda Biradar, Anasuya Sangaraj Desai, Sangappa Virupaxappa Kashinakunti, Manjula Rangappa, Gurupadappa Shantappa Kallaganad, Basavaraj Devaranavadagi


Background: Many studies have compared and correlated glycemic control markers with lipid profile in type 2 diabetes mellitus (T2DM) patients, but very few studies correlate them in impaired glucose tolerance (IGT) individuals. Thus, the aim of this study was to find comparison and correlation between FBG, PPBG and HbA1c with lipid profile in T2DM patients and IGT individuals.

Methods: The study was conducted at tertiary care hospital in north Karnataka. The diagnosis of T2DM and IGT was based on WHO criteria. 99 apparently healthy controls, 101 T2DM patients and 100 IGT subjects participated in the study.

Results: All the biochemical parameters were significantly raised in IGT and T2DM patients as compared to controls.

In T2DM, FBG showed significant positive correlation with TC (p=0.048) and significant negative correlation with HDL (p=0.000). PPBG and HbA1c showed significant positive correlation with TGL, TC VLDL and LDL and significant negative correlation with HDL, p value was 0.000 for all parameters. The correlation in IGT, FBG showed significant positive correlation with TC (p=0.000) and LDL (p=0.004), significant negative correlation with HDL (p=0.000). PPBG showed significant positive correlation with TGL, TC and VLDL and significant negative correlation with HDL(p=0.000).

Conclusions: Diagnosis of T2DM, IGT and associated dyslipidema is necessary as life style modification and pharmacotherapy can control these situations and thereby reduce the cardiovascular risk.


Impaired glucose tolerance, Lipid profile, Type 2 Diabetes mellitus

Full Text:



Powers AC. Diabetes Mellitus: Complications. In DL Kasper, AS Fauci, DL Longo, SL Hauser, JL Jameson and J Loscalzo editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill Education; 2015. p.2399.

Anonymous. Type 2 diabetes—time to change our approach. Lancet 2010;375:2193.

Kahn R. Follow-up report on the diagnosis of diabetes mellitus: the expert committee on the diagnosis and classifications of diabetes mellitus. Diabetes care. 2003;26(11):3160.

Turner R, Holman R, Matthews D, Oakes S, Bassett P, Stratton I, et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34(12):877-90.

Diabtes,Fact sheet N 312. Available at en/ Accessed on 12/12/2016.

Glycosylaed Haemoglobin, HbA1C. Availabe at moglobina1c.html?letter=h Accessed on 12/12/2016.

Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical diabetes. 2008;26(2):77-82.

Kondaveeti SB, Kumaraswamy D, Mishra S, Kumar AR, Shaker IA. Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. J Clin Diagnostic Res. 2013;7(7):1280-3.

Sirsikar M, Supriya, Mohanty S, Pinnelli VBK. Role of glycated hemoglobin (HBA1c) as a dual marker to predict glycemic status and dyslipidemia in type II diabetes mellitus. Int J Res Med Sci. 2016;4:4524-9.

Haffner SM. American Diabetes Association. Dyslipidemia management in adult with diabetes. Diabetes care 2004;27(1):S68-71.

Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733-49.

Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin North Am 2004;88:897-909.

Del Pilar Solano M, Goldberg RB. Management of diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2005;34(1):1-25.

Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2006;35(3):491-510.

Singh K, Srivastava N, Singh RL, Mahdi AA. Association between Serum Lipid Profile and Glycated Hemoglobin in Pre-diabetic Individuals. Asian J Biomed Pharmaceut Sci. 2014;4(29):30-3.

Kumar N, Singh PH, Zafar KS, Kumar G. A study of lipid profile in prediabetes. J Evid Based Med Health care. 2016;3(44):2208-12.

Delamater AM. Clinical use of hemoglobin A1c to improve diabetes management. Clinical Diabetes. 2006;24(1):6-8.

Feldt-Rasmussen B. Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int. 2006;70(8):1392-4.

Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123 (Suppl 3):S3-11.

Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421-31.

Reddy AS, Meera S, Ebenezer W. Correlation between glycemic control and lipid profile in type 2 diabetic patients: HbA1c as an indicatior of dyslipidemia. Asian J Pharm Clin Res. 2014;7:153-5.

Mahato RV, Gyawali P, Raut PS, Regmi P, Singh KP, Pandeya DR, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. Biomedical Research. 2011;22(3):375-80.

Sultania S, Thakur D, Kulshreshtha M. Study of lipid profile in type 2 diabetes mellitus patients and its correlation with HbA1c. Int J Contemp Med Res. 2017;4(2):437-9.

Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150-9.

Parveen K, Siddiqui WA, Kausara MA, Kuddusa M, Syed Monowar AS. Diabetic nephropathy - a major macrovascular complication. Int J Pharmaceuti Res Allied Sci. 2016;5:132-58.

Gantala SR, Kummari R, Tupurani MA, Galimudi RK, Gundapaneni KK, Kupsal K, et al. Evaluation of Glycemic, Lipid, Immune-Inflammatory and Oxidative Stress Markers in Various Clinical Stages of Type 2 Diabetic Nephropathy. J Metabolic Synd 2018;7: 237.

Thambiah SC, Samsudin IN, George E, ZahariSham SY, Lee HM, Muhamad MA, et al. Relationship between dyslipidaemia and glycaemicstatus in patients with type 2 diabetes mellitus. Malaysian J Pathol. 2016;38(2):123-30.

Sheikhpour R, Sadeghian F, Rajabi S. Correlation between glycated hemoglobin, serum glucose and serum lipid levels in type 2 diabetes. Iranian J Diabet Obes. 2013;5(1):12-5.

Sapkota LB, Sangita TH. Correlation between glycemic parameters and lipid profile in type 2 diabetic. J Chitwan Med Coll. 2017;7(19):20-4.

Erciyas F, Taneli F, Arslan B, Uslu Y. Glycemic control, oxidative stress and lipid profile in children with type 1 Diabetes Mellitus. Arch Med Res. 2004; 35(2):134-40.

Andersen GE, Christiansen JS, Mortensen HB, Christiansen KM, Predersen-Bjerguard L, Kastrup KW, et al. Plasma lipid and lipoprotein in type 1 diabetic children and adolescent in relation to metabolic regulation, obesity and genetic hyperlipoproteinemia. Acta Paediatar Scand. 1983;72:361-5.

Ohta T, Nishiyama S, Nakamura T, Saku K, Maung KK, Matsuda I. Predominance of large low density lipoprotein particles and lower fractional esterification rate of cholesterol in high density lipoprotein in children with insulin-dependent diabetes mellitus. Eur J Pediatr. 1998;157:276-81.

Sheth J, Shah A, Sheth F, Trivedi S, Nabar N, Shah N, et al. The association of dyslipidemia and obesity with glycated hemoglobin. Clinical Diabet Endocrinol. 2015;1(1):6.

Yan Z, Liu Y, Huang H. Association of glycosylated hemoglobin level with lipid ratio and individual lipids in type 2 diabetic patients. Asian Pacific J Trop Med. 2012;5(6):469-71.

Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC et al. Glycated hemoglobin and cardiovascular risk factors in Chinese subjects with normal glucose tolerance. Diabet Med. 1998;15(7):573-8.

Senthilkumar N, Anadasayanam A, Senthilvelu S, Rashid M. Correlation observation between HbA1C and Lipid profile in Type II Diabetes Mellitus Out-Patients. Int J Pharma Res Rev. 2016;5(5):9-20.

DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996;45(10):1289-98.

Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment and geographic location. Diabetes Care. 2007;30(5):1241-7.

Pujari SS. HbA1c as Marker of Dyslipedemia in Type 2 Diabetes Mellitus Patients. Sch J App Med Sci. 2013;1(6):728-31.